Literature DB >> 15249454

Cytokine response to pulmonary thromboendarterectomy.

Frank Langer1, Rene Schramm, Michael Bauer, Dietmar Tscholl, Takashi Kunihara, Hans-Joachim Schäfers.   

Abstract

BACKGROUND: Pulmonary thromboendarterectomy (PTE) is an effective but challenging treatment for chronic thromboembolic pulmonary hypertension (CTEPH). PTE is associated with marked hemodynamic instability in the perioperative course, suggesting the involvement of circulating mediators. The aim of this study was to characterize the expression of proinflammatory and anti-inflammatory cytokines in patients undergoing PTE.
METHODS: Fourteen patients with CTEPH (mean [+/- SD] pulmonary vascular resistance, 1,056 +/- 399 dyne.s.cm(-5)) underwent PTE using cardiopulmonary bypass (CPB) and deep hypothermic circulatory arrest (DHCA). Peripheral arterial blood samples were drawn prior to patients undergoing sternotomy, during CPB, before and after DHCA, and 0, 8, 16, 24, and 48 h after surgery. An enzyme-linked-immunosorbent assay was used to analyze the plasma levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, and IL-10. Seven patients undergoing aortic arch replacement (ARCH) in DHCA served as a control group.
RESULTS: Prior to and during PTE, the CTEPH patients exhibited elevated TNF-alpha levels, which decreased within the first 24 postoperative hours (p = 0.02). There was no TNF-alpha release among patients in the ARCH group. IL-6 levels were similar in both groups throughout the perioperative course. A profound anti-inflammatory response was observed in the PTE group, which was reflected by elevated IL-10 levels prior to surgery and a marked peak level immediately after surgery. A positive correlation was found between maximum vasopressor support and peak levels of IL-6 (r = 0.82) in the PTE patients.
CONCLUSION: Heart failure due to CTEPH appears to generate a pronounced inflammatory response with the release of proinflammatory and anti-inflammatory cytokines. PTE results in the rapid normalization of preoperatively elevated TNF-alpha levels. IL-6-mediated systemic inflammatory cascades may be involved in the regulation of peripheral vascular tone after PTE.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15249454     DOI: 10.1378/chest.126.1.135

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  19 in total

1.  Efficacy of methylprednisolone in preventing lung injury following pulmonary thromboendarterectomy.

Authors:  Kim M Kerr; William R Auger; James J Marsh; Gehan Devendra; Roger G Spragg; Nick H Kim; Richard N Channick; Stuart W Jamieson; Michael M Madani; Gerard R Manecke; David M Roth; Gordon P Shragg; Peter F Fedullo
Journal:  Chest       Date:  2011-08-11       Impact factor: 9.410

Review 2.  Chronic Thromboembolic Pulmonary Hypertension: the Bench.

Authors:  George A Alba; Deepak Atri; Sriranjani Darbha; Inderjit Singh; Victor F Tapson; Michael I Lewis; Hyung J Chun; Yen-Rei Yu; Bradley A Maron; Sudarshan Rajagopal
Journal:  Curr Cardiol Rep       Date:  2021-08-19       Impact factor: 2.931

3.  CXCL10 levels in diagnosis and improved hemodynamics in patients with chronic thromboembolic pulmonary hypertension undergoing balloon pulmonary angioplasty.

Authors:  Cheng Hong; Jianmin Lu; Riken Chen; Haimin Liu; Haiming Chen; Xiaofeng Wu; Wenliang Guo; Zijie Huang; Huizhao Liao
Journal:  Pulm Circ       Date:  2022-06-07       Impact factor: 2.886

4.  Comparison of gene expression profiles and related pathways in chronic thromboembolic pulmonary hypertension.

Authors:  Song Gu; Pixiong Su; Jun Yan; Xitao Zhang; Xiangguang An; Jie Gao; Rui Xin; Yan Liu
Journal:  Int J Mol Med       Date:  2013-12-10       Impact factor: 4.101

Review 5.  Chronic thromboembolic pulmonary hypertension: time for research in pathophysiology to catch up with developments in treatment.

Authors:  Mark Toshner; Joanna Pepke-Zaba
Journal:  F1000Prime Rep       Date:  2014-06-02

6.  Pretreatment with Erythropoietin Attenuates Lung Ischemia/Reperfusion Injury via Toll-Like Receptor-4/Nuclear Factor-κB (TLR4/NF-κB) Pathway.

Authors:  Qian He; Xueshan Zhao; Siwei Bi; Yu Cao
Journal:  Med Sci Monit       Date:  2018-03-01

7.  The role of mononuclear cell tissue factor and inflammatory cytokines in patients with chronic thromboembolic pulmonary hypertension.

Authors:  Minxia Yang; Chaosheng Deng; Dawen Wu; Zhanghua Zhong; Xiaoting Lv; Zhihua Huang; Ningfang Lian; Kaixiong Liu; Qiaoxian Zhang
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

8.  Resolvin D1 mitigates energy metabolism disorder after ischemia-reperfusion of the rat lung.

Authors:  Qifeng Zhao; Ji Wu; Qingwang Hua; Zhiyong Lin; Leping Ye; Weixi Zhang; Guowei Wu; Jie Du; Jie Xia; Maoping Chu; Xingti Hu
Journal:  J Transl Med       Date:  2016-03-24       Impact factor: 5.531

9.  Resolvin D1 Alleviates the Lung Ischemia Reperfusion Injury via Complement, Immunoglobulin, TLR4, and Inflammatory Factors in Rats.

Authors:  Qifeng Zhao; Ji Wu; Zhiyong Lin; Qingwang Hua; Weixi Zhang; Leping Ye; Guowei Wu; Jie Du; Jie Xia; Maoping Chu; Xingti Hu
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

10.  Fibrinogen plasma concentration is an independent marker of haemodynamic impairment in chronic thromboembolic pulmonary hypertension.

Authors:  Jan K Hennigs; Hans Jörg Baumann; Nicole Lüneburg; Gesine Quast; Lars Harbaum; Jan Heyckendorf; Karsten Sydow; Bernhard Schulte-Hubbert; Michael Halank; Hans Klose
Journal:  Sci Rep       Date:  2014-04-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.